par Hoffmann, Paul;Roumeguere, Thierry 
;Schulman, Claude ;Van Velthoven, Roland
Référence The New England journal of medicine, 355, 25, page (2705-2707)
Publication Publié, 2006-12
;Schulman, Claude ;Van Velthoven, Roland Référence The New England journal of medicine, 355, 25, page (2705-2707)
Publication Publié, 2006-12
Article révisé par les pairs
| Titre: |
|
| Auteur: | Hoffmann, Paul; Roumeguere, Thierry; Schulman, Claude; Van Velthoven, Roland |
| Informations sur la publication: | The New England journal of medicine, 355, 25, page (2705-2707) |
| Statut de publication: | Publié, 2006-12 |
| Sujet CREF: | Cancérologie |
| MeSH keywords: | Adjuvants, Immunologic |
| BCG Vaccine | |
| Carcinoma in Situ -- therapy | |
| Cholesterol -- blood | |
| Cytokines -- drug effects -- urine | |
| Follow-Up Studies | |
| Humans | |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors -- adverse effects | |
| Neoplasm Recurrence, Local -- epidemiology | |
| Retrospective Studies | |
| Th1 Cells -- drug effects | |
| Th2 Cells -- drug effects | |
| Treatment Outcome | |
| Urinary Bladder Neoplasms -- therapy | |
| Note générale: | Letter |
| SCOPUS: le.j | |
| Langue: | Anglais |
| Identificateurs: | urn:issn:0028-4793 |
| info:doi/10.1056/NEJMc062714 | |
| info:pii/355/25/2705 | |
| info:scp/33845700951 | |
| info:pmid/17183004 |
